Search

everythinglearnresearchcommunity

for

Search:↓

Postgraduate dermatology students should focus on practical training, core dermatology, and systematic learning, especially in their second and third years.

The convention highlighted the importance of comprehensive patient care and early diagnosis in dermatology.

MicroRNAs are important for skin health and could be targets for new skin disorder treatments.

Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.

Personalized homeopathic treatment may help manage alopecia areata.

In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.

Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.

A new botanical treatment improved hair growth and symptoms in lichen planopilaris patients.

Chemotherapy can cause brain inflammation and damage, and understanding this process could help manage side effects.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

New treatments offer hope for better managing hidradenitis suppurativa.

Certain immune cells in the skin release a protein that stops hair growth by keeping hair stem cells inactive.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Abrocitinib may effectively treat stubborn alopecia universalis.

Alopecia areata is hard to treat, but new targeted therapies show promise.

Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.

Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.

Ruxolitinib can cause a delayed skin reaction on the nose.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

Ritlecitinib can reduce inflammation and help hair regrow in Alopecia Areata.

Hair follicles are key to treating vitiligo and alopecia areata, but challenges exist.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

A PTH-based treatment improved hair regrowth better than ruxolitinib in a mouse model of hair loss.

Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.